Receptor News and Research

RSS

Human tumors with MET amplification respond to MET inhibitor drugs

A subset of colorectal cancers responds to anti-epidermal growth factor receptor (anti-EGFR) therapies, but develops resistance within months. Among cancers that develop resistance to anti-EGFR therapy, some showed overexpression of a gene called MET, according to a study published in the June issue of Cancer Discovery, a journal of the American Association for Cancer Research.

3 Jun 2013

Mount Sinai researchers present landmark studies at ASCO meeting

Icahn School of Medicine at Mount Sinai researchers will present several landmark studies at the 2013 American Society of Clinical Oncology meeting May 31-June 4, 2013 in Chicago, including data on the likelihood of spousal human papillomavirus oral infection, new gene signatures in melanoma, and issues with high readmission rates after cancer surgery.

3 Jun 2013

Concerns raised about popular blood pressure, diabetes drugs

The Wall Street Journal reports that a senior FDA regulator is seeking stronger warnings about a class of blood pressure drugs that may be linked to higher cancer rates. Meanwhile, The New York Times details how a doctor hired by Merck to test a diabetes drug in rats found a possible link to pancreatic cancer, a discovery that turned the doctor into a crusader.

1 Jun 2013

NanoString Technologies to present clinical study of Prosigna Breast Cancer Assay at ASCO 2013

NanoString Technologies, Inc., a privately held provider of life science tools for translational research and molecular diagnostic products, today announced that a clinical study of the Prosigna Breast Cancer Assay will be presented during the Breast Cancer Oral Abstract Session at the 2013 Annual American Society of Clinical Oncology Meeting on Sunday, June 2.

From NanoString Technologies 1 Jun 2013

Researchers discover potential biomarkers to identify patients with head and neck cancer

Researchers from Fox Chase Cancer Center will present data at the 49th Annual Meeting of the American Society of Clinical Oncology on Saturday, June 1, which shows the discovery of potential biomarkers that may be used to identify patients with head and neck cancer whose tumors are unlikely to respond to treatment by the targeted therapy cetuximab-a type of monoclonal antibody.

1 Jun 2013

Findings could potentially lead to new drug therapy for Cushing disease

Cushing disease is a life-threatening disorder most commonly triggered by tumors, often benign, in the pituitary glands, resulting in excess production of adrenocorticotrophic hormone.

1 Jun 2013

Study points to synergistic relationship between lead exposure and schizophrenia gene

Mice engineered with a human gene for schizophrenia and exposed to lead during early life exhibited behaviors and structural changes in their brains consistent with schizophrenia.

1 Jun 2013

GLYX-13 drug induces antidepressant results without street drug side effects

GLYX-13, a molecular cousin to ketamine, induces similar antidepressant results without the street drug side effects, reported a study funded by the National Institute of Mental Health (NIMH) that was published last month in Neuropsychopharmacology.

31 May 2013

First Edition: May 31, 2013

Today's early morning highlights from the major news organizations, including reports from the administration about the number of insurers that will be offering policies on the new online marketplaces.

31 May 2013

Novel approach to create unlimited number of human red blood cells, platelets in vitro

A study led by Boston University School of Medicine has identified a novel approach to create an unlimited number of human red blood cells and platelets in vitro. In collaboration with Boston University School of Public Health and Boston Medical Center, the researchers differentiated induced pluripotent stem cells into these cell types, which are typically obtained through blood donations.

31 May 2013

Oncothyreon, Array BioPharma to develop and commercialize ARRY-380 for breast cancer patients

Oncothyreon Inc. and Array BioPharma Inc. today announced that they will collaborate to develop and commercialize ARRY-380, an orally active, reversible and selective small-molecule HER2 inhibitor.

30 May 2013

Researchers develop new gene therapy to thwart potential influenza pandemic

Researchers at the Perelman School of Medicine, University of Pennsylvania have developed a new gene therapy to thwart a potential influenza pandemic. Specifically, investigators in the Gene Therapy Program, Department of Pathology and Laboratory Medicine, directed by James M. Wilson, MD, PhD, demonstrated that a single dose of an adeno-associated virus expressing a broadly neutralizing flu antibody into the nasal passages of mice and ferrets gives them complete protection and substantial reductions in flu replication when exposed to lethal strains of H5N1 and H1N1 flu virus.

30 May 2013

Findings could lead to better understanding of learning and memory

Students preparing for final exams might want to wait before pulling an all-night cram session - at least as far as their neurons are concerned. Carnegie Mellon University neuroscientists have discovered a new intermediate phase in neuronal development during which repeated exposure to a stimulus shrinks synapses.

30 May 2013

Atopix awarded grant to pursue development of OC459 for atopic dermatitis

Atopix Therapeutics Ltd, a biopharmaceutical company developing a novel class of anti-allergic medicines, has been awarded a £1.7 million grant from the UK Biomedical Catalyst fund to pursue development of OC459 in the treatment of moderate-to-severe atopic dermatitis (a form of eczema).

29 May 2013

Viewpoints: 'Good news' on Calif. insurance rates; Battle against dementia needs stronger efforts; Dental care for the disabled

The Affordable Care Act, a k a Obamacare, goes fully into effect at the beginning of next year, and predictions of disaster are being heard far and wide. ... No doubt there will be problems, as there are with any large new government initiative, and in this case, we have the added complication that many Republican governors and legislators are doing all they can to sabotage reform. Yet important new evidence - especially from California, the law's most important test case - suggests that the real Obamacare shock will be one of unexpected success (Paul Krugman, 5/26).

29 May 2013

Scientists discover new function of an enzyme that disposes of superfluous proteins

Cells have a sophisticated system to control and dispose of defective, superfluous proteins and thus to prevent damage to the body. Dr. Katrin Bagola and Professor Thomas Sommer of the Max Delbr-ck Center for Molecular Medicine Berlin-Buch as well as Professor Michael Glickman and Professor Aaron Ciechanover of Technion, the Technical University of Israel in Haifa, have now discovered a new function of an enzyme that is involved in this vital process.

29 May 2013

Research discovery may lead to development of new therapies for neurological disorders

For several years, the pharmaceutical industry has tried to develop drugs that target a specific neurotransmitter receptor in the brain, the NMDA receptor. This receptor is present on almost every neuron in the human brain and is involved in learning and memory. NMDA receptors also have been implicated in several neurological and psychiatric conditions such as Alzheimer's disease, Parkinson's disease, schizophrenia and depression.

29 May 2013

Receptor News and Research

Human tumors with MET amplification respond to MET inhibitor drugs

Mount Sinai researchers present landmark studies at ASCO meeting

Concerns raised about popular blood pressure, diabetes drugs

NanoString Technologies to present clinical study of Prosigna Breast Cancer Assay at ASCO 2013

Researchers discover potential biomarkers to identify patients with head and neck cancer

Findings could potentially lead to new drug therapy for Cushing disease

Study points to synergistic relationship between lead exposure and schizophrenia gene

GLYX-13 drug induces antidepressant results without street drug side effects

First Edition: May 31, 2013

Novel approach to create unlimited number of human red blood cells, platelets in vitro

Oncothyreon, Array BioPharma to develop and commercialize ARRY-380 for breast cancer patients

Researchers develop new gene therapy to thwart potential influenza pandemic

Findings could lead to better understanding of learning and memory

Atopix awarded grant to pursue development of OC459 for atopic dermatitis

Viewpoints: 'Good news' on Calif. insurance rates; Battle against dementia needs stronger efforts; Dental care for the disabled

Scientists discover new function of an enzyme that disposes of superfluous proteins

Research discovery may lead to development of new therapies for neurological disorders

New approach to battle prostate cancer

UT Southwestern researchers develop new class of drugs for prostate cancer

Astellas submits application for marketing approval of enzalutamide for prostate cancer

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News